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ABSTRACT
Sommerville, Sherilyn M. Effects Of A Twelve Week Aerobic Training And Strength
Training Intervention On Chemotherapy-Induced Peripheral Neuropathy.
Unpublished Master of Science Thesis, University of Northern Colorado, 2015.
Chemotherapy is one of the most effective cancer treatments to date; however, it
has the potential to produce debilitating life-long side effects. Chemotherapy-induced
peripheral neuropathy is a side effect caused by toxic chemotherapy agents that
deteriorate the peripheral nerves of the body. Research has suggested that aerobic and
strength training may be able to alleviate some of the symptoms associated with
chemotherapy-induced peripheral neuropathy. Some of the benefits of both aerobic and
strength training include increasing blood and nutrient flow to the peripheral nerves,
which could help restore sensation and alleviate the some symptoms of chemotherapyinduced peripheral neuropathy. However, to our knowledge, there is little research
evaluating the effects of an aerobic and strength-training intervention on chemotherapyinduced peripheral neuropathy. Purpose: The purpose of this study was to examine the
effects of a 12-week aerobic and strength training intervention on the symptoms of
chemotherapy-induced peripheral neuropathy. Methods: Ten participants (aged 48-76)
participated in a 12-week exercise intervention and completed a pre-, mid-, and post4.17/1g Semmes Weinstein Monofilament Test and 5.07/10g Semmes Weinstein
Monofilament Test. A comprehensive physical assessment was completed before and
after the 12-week intervention. Results: Wilk’s Lambda Multivariate analysis of variance
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revealed significant (p < 0.05) changes from pre-, mid-, and post- 4.17/1g Semmes
Weinstein Monofilament Test scores. However, there were no significant (p < 0.05)
results detected with the 5.07 Semmes Weinstein Monofilament test. Paired samples ttests revealed significant (p < 0.05) differences between aerobic and several strength tests
from pre- to post-assessment. Several psychological scores improved significantly (p <
0.05) as well from pre- to post- assessment. Conclusion: Significant improvements were
observed for the 4.17/1g Semmes Weinstein Monofilament test following a 12-week
aerobic and strength training intervention for subjects experiencing chemotherapyinduced peripheral neuropathy. These results suggest that aerobic and strength training
may contribute to a reduction in chemotherapy-induced peripheral neuropathy.
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CHAPTER I

INTRODUCTION
The American Cancer Society estimates that there were 14.5 million Americans
living with cancer in 2014 (American Cancer Society, 2015). Every year cancer rates
continue to increase even with advances in modern medicine. The most common
treatments for cancer include surgery, chemotherapy, radiation therapy, and hormone
therapy. When diagnosed with cancer, chemotherapy is one of the effective forms of
treatment that can prolong survival (Malik & Stillman, 2008). There are numerous types
and combinations of chemotherapy treatments available; however, they all have the
potential of producing debilitating side effects.
One of the major side effects of chemotherapy treatments is chemotherapyinduced peripheral neuropathy (CIPN). Thirty to forty percent of all patients receiving
chemotherapy will experience CIPN, which is a type of peripheral neuropathy that is
caused by certain chemotherapy agents (Pignataro & Swisher, 2010). Peripheral
neuropathy is defined as any damage that occurs to the peripheral nerves and enables
them to function properly. Neuropathic symptoms include pain, numbness, tingling,
decreased motor function, weakness, and any type of paresthesia or dysesthesia (Kluding
et al., 2012; Pignataro & Swisher, 2010; Hausheer, Schilsky, Bain, Berghorn, &
Lieberman, 2006; Kochman, Carnegie, & Burke, 2002). Several theories have suggested
how chemotherapy causes neuropathy. Specifically with platinum drugs, such as cisplatin
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or carboplatin, pre-mature cell apoptosis may be occurring (Argyriou, Bruna, Marmiroli,
& Cavaletti, 2012). It has been theorized that taxane chemotherapy drugs interfere with
the microtubules of the mitotic spindle, which in turn interferes with axonal transport,
thereby affecting the somatosensory neurons and causing destruction of distal nerve
endings (Argyriou et al., 2012). Taxane chemotherapy has also been shown to disrupt
Schwann cells, which leads to many issues within the axonal membranes, and can disrupt
the myelination of the axon terminals (Quasthoff & Hartung, 2002; Persohn et al., 2005;
Wickham, 2007). Platinum chemotherapies such as cisplatin, carboplatin, and oxaliplatin,
have been shown to disrupt the cytoplasmic and nuclear components of an axon and
disrupt axonal transport ultimately (Wickham, 2007). The exact cause behind CIPN is
still unknown; however, exercise may be a viable method to alleviate the symptoms.
Within the past ten years, exercise has shown to benefit cancer patients
tremendously and reduce cancer-related side effects (Hsieh et al., 2008; Schneider, Hsieh,
Sprod, Carter, & Hayward, 2007a; Schneider, Hsieh, Sprod, Carter, & Hayward, 2007b).
Major cancer-related side effects include toxicities to major organ systems in the body
along with fatigue, psychological issues, lymphedema, pain, body image problems,
depression, anxiety, and sleep disturbances (Schneider et al., 2007a; Schneider et al.,
2007b; Schneider, Dennehy, & Carter, 2003). Some of the toxicities that present include
immune system toxicity, cardiovascular toxicity, pulmonary toxicity, gastrointestinal
toxicity, hepatic toxicity, neuroendocrine toxicity, nephrotoxicity, and dermatological
toxicity (Schneider et al., 2003). Exercise has been shown to improve the cardiovascular
system, respiratory system, metabolic system, neuromuscular system, and endocrine
system (Schneider et al., 2003). When cancer patients exercise, they may also experience
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a reduction in chemotherapy-related side effects. However, very few studies have been
conducted to examine the effects of exercise on CIPN.
Previous research has theorized that strength training and aerobic training may
help alleviate CIPN (Kluding et al., 2012; Tofthagen, Visovsky, & Berry, 2012). Kluding
et al., (2012) found significant evidence that an aerobic and strength training intervention
helped to reduce the pain and symptoms associated with diabetic peripheral neuropathy.
Symptoms of CIPN are assessed in a variety of ways. Nerve conduction tests, Semmes
Weinstein monofilament tests (SWMT), and the Michigan Neuropathy Screening
Instrument (MNSI) are common ways to assess CIPN currently. However, there is no
gold standard for assessing CIPN. Research has shown SWMT can be a beneficial
instrument to assess CIPN over time using a composite score (Tan, 2010; Feng,
Schlösser, & Sumpio, 2009; Kamei et al., 2005; Lee et al., 2003; Kochman et al., 2002;
Olaleye, Perkins, & Bril, 2001; Kumar et al., 1991). To date, no studies have evaluated
the effects of an aerobic and strength training exercise intervention on CIPN.
Statement of Purpose

	
  

The purpose of this study was to examine the effects of a 12-week aerobic and
strength training intervention on the symptoms of chemotherapy-induced peripheral
neuropathy.
Research Hypothesis

	
  
H

	
  

	
  

Participants who are experiencing CIPN and participating in the strength
training and aerobic training intervention will show improvements in
CIPN symptoms. Potential improvements would translate to lower CIPN
composite assessment scores.
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Significance of Study
Patients who have received chemotherapy treatment can potentially develop CIPN

as a life-long side effect, which could lead to an overall decrease in quality of life if left
untreated (Kluding et al., 2012; Pignataro & Swisher, 2010; Hausheer et al., 2006;
Kochman et al., 2002). CIPN can decrease the quality of life for many patients and inhibit
them from activities of daily living. Exercise has already shown to reduce chemotherapyrelated side effects for other major toxicities, and may potentially reduce CIPN symptoms
(Schneider et al., 2007a; Schneider et al., 2003; Kluding et al., 2012; Tofthagen et al.,
2012). To date no research exists that evaluates the effects of strength training and
aerobic training on the severity of CIPN. If in fact, exercise training regimens that include
both aerobic and resistance components can alleviate CIPN, such interventions should be
considered for all cancer patients experiencing peripheral neuropathies.
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CHAPTER II

REVIEW OF LITERATURE
Chemotherapy-Induced
Peripheral Neuropathy
Chemotherapy-Induced Peripheral Neuropathy can be described as damage to the
peripheral nerves as a result of exposure to chemotherapy toxic agents. Every
chemotherapeutic drug is unique and each drug can potentially damage peripheral nerves
differently. Platinum drugs, taxanes, epothilones, vinca alkaloids, bortezomib, and
thalidomide are the most common chemotherapeutic agents that cause CIPN (Wolf,
Barton, Kottschade, Grothey, & Loprinzi, 2008; Hausheer et al., 2006). These toxic
agents affect both small and large fiber axons (Wolf et al., 2008; Schloss et al., 2013;
Kluding et al., 2012). Small fibre axons are unmyelinated and are responsible for sensing
temperature and pain (Wolf et al., 2008; Schloss et al., 2013), while large fibre axons are
myelinated and are responsible for sensing position, vibration, and motor control (Wolf et
al., 2008; Schloss et al., 2013). While these drugs are unable to cross the blood brain
barrier (Schloss et al., 2013) the peripheral nervous system does not have a protective
barrier and it is susceptible to these agents.
At the cellular level, platinum drugs may alter the DNA of peripheral nerve cells
by causing an overproduction of cyclin D1 expression and hyper-phosphorylation of the
retinoblastoma gene, which can lead to apoptosis or ultimately peripheral neuropathy
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(Argyriou et al., 2012). Another possibility is that there could be a disruption in
mitochondrial function within the cells, which causes oxidative stress and triggers
neuronal apoptosis (Argyriou et al., 2012). Some platinum agents, specifically
oxaliplatin, have been hypothesized to cause CIPN due to chelation of calcium from
neural membranes (Hausheer et al., 2006). These could be possible mechanisms
explaining CIPN with platinum based chemotherapy.
Another major chemotherapy drug group, the taxane, causes a disruption in the
microtubules of the mitotic spindle, which interferes with axonal transport in the axons as
well as the soma of somatosensory neurons (Argyriou et al., 2012). It has also been
observed that taxane drugs initiate death of the peripheral nerves, starting from the distal
nerve endings and ultimately causing a disturbance of cytoplasmic flow within the neuron
itself (Quasthoff & Hartung, 2002; Argyriou et al., 2012). Taxanes also have deleterious
effects on excitability of sensory and motor nerves due to an axonal membrane leak and a
non-specific ion influx (Quasthoff & Hartung 2002). In order for a membrane to
depolarize correctly, the correct exchange of sodium and potassium must occur across the
membrane. If ions are crossing the membrane in a disorderly fashion, problems may arise
with message and cell signaling. Like taxane drugs, epothilones have a similar effect on
the neuron. Epothilones have been found to cause polymerization of the tubulin in
microtubules in the absence of guanosine triphosphate, which is needed in a healthy cell
to polymerize (Argyriou et al., 2012). The preformed tubulin is then put into
depolymerizing conditions, which ultimately lead to the destruction of the microtubules
(Argyriou et al., 2012).

	
  

7
The vinca alkaloids group of chemotherapy drugs includes vinblastine,
vincristine, vinorelbine, and vinesine drugs (Hausheer et al., 2006). Vinca alkaloids
ultimately lead to cell death due to an arrest of dividing cells during the metaphase stage
of development (Argyriou et al., 2012). The vinca alkaloids cause alterations in the
neuronal cytoskeleton due to binding on the intracellular tubulin, which leads to
alterations in axonal transport, buildup of neurofilaments in the cell bodies and proximal
axons, and accumulation of axoplasmic organelles and vesicles (Quasthoff & Hartung
2002; Argyriou et al., 2012). There is also a reduction in myelin thickness and shortening
of inter-nodal length that occurs (Argyriou et al., 2012).
The pathogenesis of bortezomib and thalidomide are still unknown to researchers.
Theories suggest that bortezomib interferes with transcription, nuclear processing,
nuclear transport, and cytoplasmic translation of mRNA’s in dorsal root ganglion
neurons. This can ultimately affect the signaling cascade within the neuron and can lead
to cytotoxicity (Hausheer et al., 2006). Thalidomide is hypothesized to causes
angiogenesis inhibition, immunomodulation, and cytokine modulation (Argyriou et al.,
2012). By inhibiting angiogenesis, the formation of new blood vessels, the body may be
depriving itself of blood circulation starting with the peripheries first. Also,
immunomodulation may be beneficial for some patients with cancer because it allows
medical professionals to essentially modify the immune system, but it may be detrimental
to the peripheral nerves. However, much research still needs to be performed to clearly
understand the effects of thalidomide and bortezomib.
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Symptoms of Chemotherapy-Induced
Peripheral Neuropathy
The symptoms for CIPN are similar and have found to be dose-dependent across
all chemotherapy drugs (Schloss et al., 2014; Wolf et al., 2008; Quasthoff & Hartung
2002). This infers that higher cumulative doses of chemotherapy may result in longer and
more severe CIPN. This is detrimental to the patient because if the CIPN escalates, it can
cause secession of the chemotherapy. Also, different chemotherapy drugs will elicit
different symptoms of CIPN. Many CIPN patients complain of a “glove-and-stocking”
feeling and distribution (Schloss et al., 2013). This can be best described as the patient
feeling as if they are always wearing gloves and socks on their hands or feet. CIPN can
also present as numbness, tingling, pain, decreased motor function, weakness, and any
type of paresthesia or dysesthesia (Kluding et al., 2012; Hausheer et al., 2006; Kochman
et al., 2002). Another symptom of CIPN is the inability to sense temperature (Wilkes,
2007). It ultimately leads to a diminished quality of life, chronic discomfort, reduced
physical activity, reduced dexterity, and in some cases ulceration, which can lead to
amputation (Schloss et al., 2014; Speck et al., 2012; Feng et al., 2009; Lee et. al., 2003;
Kumar et al., 1991).
Chemotherapy-Induced
Peripheral Neuropathy Testing
Currently there is no gold standard for the testing of CIPN. However, the Semmes
Weinstein Monofilament Test (SWMT) has been shown to be a beneficial instrument for
the testing of all peripheral neuropathy (Tan, 2010; Feng et al., 2009; Kamei et al., 2005;
Lee et al., 2003; Kochman et al., 2002; Olaleye et al., 2001; Kumar et al., 1991). The
SWMT consists of several different nylon monofilaments of varying gauges and forces.
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The monofilament is applied to the surface of the skin and force is applied until the
monofilament bends. The monofilament will buckle at a set force, which helps control for
variability between tests and is reproducible (Feng et al., 2009; Kumar et al., 1991).
These monofilaments can measure the subject’s cutaneous pressure perception threshold
(Kumar et al., 1991). The 5.07/10 g SWMT is the most commonly used monofilament by
clinicians and researchers, as the inability to sense this gauge suggests the loss of
protective sensation and an increased risk of foot ulceration (Feng et al., 2009; Tan, 2010;
Lee et al., 2003; Olaleye et al., 2001; Kamei et al., 2005; Leonard, Farooqi, & Myers,
2004; Kumar et al., 1991). The 5.07/10g SWMT has been validated against nerve
conduction tests and vibration perception threshold tests, and were all found to be
correlated with each other (Feng et al., 2009; Kamei et al., 2005; Lee et al., 2003; Olaleye
et al., 2001; Kumar et al., 1991). The 4.17/1g SWMT is commonly used alongside the
5.07/10g SWMT due to its ability to detect a diminishing protective sensation (Lee et al.,
2003; Callahan, Hunter, & Mackin, 1995; Kumar et al., 1991). The 4.17/1g SWMT may
be useful in the early detection of peripheral neuropathy. Due to the fact that very little
research regarding CIPN has been conducted, many of the studies examined pertained to
diabetic peripheral neuropathy. Therefore, these findings may be relevant for diabetic
peripheral neuropathy, but CIPN may be more responsive to other testing instruments.
Similarly to the testing modality, there is no agreement over which sites and how
many sites on the hands and feet should be tested. The first, third, and fifth metatarsal
head have consistently been shown to be positive indicators of peripheral neuropathy, and
have a 94% accuracy of identifying peripheral neuropathy (Tan, 2010; Lee et al., 2003).
The peripheral nerves that lie within the foot branch through the foot and include: 1)
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medial plantar nerves which innervate the first through third metatarsal head along the
medial plantar aspect of the foot; 2) the lateral plantar nerve which innervates the fourth
and fifth metatarsals along the lateral plantar aspect of the foot; 3) the saphenous nerve
which innervates the arch of the foot; 4) the sural nerve which innervates the most lateral
aspect of the foot; 5) the tibial nerve which innervates the calcaneus; 6) the deep peroneal
nerve which innervates the majority of the dorsal surface of the foot; and 7) the deep
peroneal nerve which innervates the dorsal surface of the foot in-between the first and
second metatarsals (Tortora & Derrickson, 2009). In the hand: 1) the median nerve
innervates the palmar surface of the first, second, third, and half of the fourth phalanges
and metacarpals, 2) the ulnar nerve innervates half of the fourth phalange and
metacarpal., as well as the fifth phalange and metacarpal, and 3) the radial nerve
innervates the most lateral aspect of the first metacarpal (Tortora & Derrickson, 2009).
Strength and Aerobic Training Benefits
in Chemotherapy-Induced
Peripheral Neuropathy
There is very little research regarding the effects of strength and aerobic training
on peripheral neuropathy. Some studies have shown that exercise can improve balance,
improve gait patterns, and decrease the risk of falls in neuropathic patients, yet
neuropathic symptoms were not assessed over time (Tofthagen et al., 2012). One study
did find that a 10-week exercise intervention improved a selected measure of peripheral
nerve function (Kluding et al., 2012). Kluding et al., (2012) designed a 10-week exercise
program consisting of aerobic and strength training exercises. The aerobic exercise was
kept at a moderate level, 50%-70% of VO2 reserve, and strength training was performed
at a moderate range as well; rate of perceived exertion (RPE) of 7-8 out of 10 on the
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modified Borg scale. Health professionals monitored the exercise and results were based
on the Michigan Neuropathy Screening Instrument (MNSI). The MNSI is a survey
conducted by a health professional that includes a lengthy physical assessment and a
medical history section. However, this study presented major limitations including short
intervention duration, small sample size, lack of a control group, and limited knowledge
of CIPN (Kluding et al., 2012). Along with the cellular level disruptions chemotherapy
agents can cause, they may also induce sensory or motor neuropathy by activating
mitochondrial and vascular dysfunction (Tofthagen et al., 2012). However, research has
supported the assumption that exercise stimulates endoneurial blood flow and
mitochondrial protein synthesis and glycolysis which both have the ability to generate
energy (Tofthagen et al., 2012). Aerobic exercise specifically has been shown to enhance
axon regeneration after peripheral nerve injury (Sabatier, Redmon, Schwartz, & English,
2008). This could be due to an up regulation in neurotropic factors that occur with
exercise and increased neuronal activity (Sabatier et al., 2008). Neurotropic factors are
responsible for growth and maintenance of neurons within the body (Widmaier, Raff, &
Strang, 2006). Strength exercise has also been thought to enhance nerve re-innervation
(Wilkes, 2007). Exercise could ultimately increase the supply of blood, oxygen, and other
essential nutrients to the mitochondria, and then to the peripheral nerves, which could
result in fewer neuropathic symptoms (Tofthagen et al., 2012). Benefits of exercise on
peripheral nerve damage have not received much attention in research. The lack of
research in this area demonstrates a need for studies investigating the beneficial effects of
exercise on CIPN.
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CHAPTER III

	
  

METHODS
Experimental Design
	
  
The purpose of this study was to examine the effects of a 12-week aerobic and
strength training intervention on the symptoms of chemotherapy-induced peripheral
neuropathy. This study consisted of a pre-to-posttest design. Pre and post physical
assessments were conducted on each participant to establish whether a training effect and
if any physiological improvements occurred. The pre and post assessments consisted of a
neuropathy screening, physiological screenings, and psychological screenings. Baseline
measurements were gathered prior to and following each individual exercise intervention.
A peripheral neuropathy screening was performed prior to the intervention, at 6 weeks,
and at 12-weeks to evaluate changes in chemotherapy-induced peripheral neuropathy
(CIPN) symptoms.
Preliminary Paperwork
	
  
Before entering the RMCRI program and inclusion into the study, each participant
was asked to complete questionnaires and surveys, which included a medical history,
cancer history, and a lifestyle and activity evaluation. The cancer and medical history
established pertinent information about cancer diagnosis, cancer stage, past and current
treatments, pre-existing conditions, and limitations and considerations for exercise. The
lifestyle and activity evaluation was administered to help establish lifestyle choices, such
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as previous and current activity levels, tobacco use, alcohol use, and fluctuations in body
weight. Psychological measures were evaluated using the Beck Depression Inventory
(Salkind, 1969), the Piper Fatigue Scale (Piper et al., 1998), and the Ferrans and Powers
Quality of Life Index Cancer Version III (Ferrans & Powers, 1985). Each participant was
asked to complete surveys and questionnaires prior to each pre-and-post assessment.
	
  

Participants
Fifteen participants were recruited for this study. Each cancer patient was

referred to the Rocky Mountain Cancer Rehabilitation Institute (RMCRI) from the local
medical community. Patients were then screened for the cancer exercise rehabilitation
program through RMCRI at the University of Northern Colorado to establish eligibility
for the study. The inclusion criteria for this study consisted of: 1) must be at least 18
years of age; 2) have been diagnosed with cancer; 3) have received chemotherapy
treatment for cancer in the past or currently be undergoing chemotherapy treatment; 4)
must have been experiencing self-reported neuropathy in either hands or feet; 5) have had
no serious co-morbidities such as diabetes; and 6) been cleared by a physician for
exercise. Exclusion criteria for this study consisted of: 1) diagnosis of Type I or Type II
diabetes; 2) past or present alcohol abuse or substance abuse; 3) history of central
nervous system dysfunction prior to a cancer diagnosis; or 4) currently receiving
pharmacological interventions for CIPN or other forms of intervention for the
management of CIPN. Participants who met these criteria and were willing to participate
were assigned to a specific training phase and exercise intervention following the initial
assessment. The participants were informed of the nature of the exercise intervention and
that they would be trained by a certified Cancer Exercise Specialist at RMCRI. To obtain
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the appropriate weights and intensities, the initial assessment values were used. After the
participants were informed and understood the study and the protocols, they signed a
copy of the informed consent, which was approved by the University of Northern
Colorado Institutional Review Board (see Appendix 1). As per the directions on the
informed consent, a copy was also made available for them to keep.
Assessment

	
  

Physiological measurements were evaluated during the initial and post
assessment. These measures included balance, cardiovascular endurance, pulmonary
function, body composition, functional movement, flexibility, and muscular strength and
endurance. During both the pre and post assessments, a heart rate monitor (Polar, Inc.
Lake Success, NY) was worn by each participant at all times to monitor heart rate
response to exercise. Blood pressure and oxygen saturation were also measured at the
beginning and end of the assessment with a sphygmomanometer and pulse oximeter,
respectively.
Cardiovascular Assessment
Cardiovascular endurance was evaluated using RMCRI’s VO2peak treadmill test.
This protocol has been found to be more accurate and appropriate for cancer survivors
due to the sensitivity of the population (Shackelford, Brown, Lalonde, Hydock, &
Schneider, 2012). The objective of the test is to allow the participant to reach selfperceived maximal exhaustion or fatigue, and the highest measurement of oxygen
consumption was recorded. For RMCRI’s treadmill protocol, heart rate and oxygen
saturation were recorded and obtained at the end of each minute/stage, blood pressure and
RPE was obtained and recorded at the end of each third minute, and speed and/or grade
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increased at the end of each minute. Termination of the test occurred when the participant
reached volitional fatigue, asked to stop, or the Cancer Exercise Specialist felt the test
needed to be terminated due predetermined termination criteria. The criteria for
terminating the VO2peak test included: drop in systolic blood pressure of more than 10
mmHg, heart rate does not increase with increased intensity, diastolic blood pressure
fluctuates more than 10 mmHg from baseline, or oxygen saturation dropped below 80 on
the pulse oximeter (Arena, 2014). The time in which VO2peak was established was
recorded in standard and decimal form, as well as whether the participant was running or
walking and if handrails were used. VO2 values were obtained utilizing ACSM metabolic
equations.
Strength and Muscular Endurance
Strength was assessed using the estimated 1-repetition maximum test along with
the Brzycki equation (Brzycki, 1993). This information allowed the Cancer Exercise
Specialist to write an accurate exercise prescription and progress the participant
appropriately. Muscular endurance was evaluated using the handgrip test (Mathiowetz,
Weber, Volland, & Kashman, 1984), core/plank test, and the chair squat test, which
indicated the level of muscular fatigue the participant experienced. These tests also
helped to indicate which muscle groups would need more endurance training through the
intervention.
Estimated 1-Repetiton Max Assessment. Muscular strength was estimated via
the Brzycki equation using an estimated 1-repetition max (est. 1-RM) test. The exercises
assessed were the latissimus dorsi (lat) pull-down, shoulder press, chest press, seated row,
leg press, leg extension, and leg curl using Cybex Eagle weight resistance machines
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(Cybex International., Inc., Medway, MA). The researchers demonstrated how to perform
each exercise and the seat was adjusted to an estimate of proper fit for the participant.
With an appropriate weight, the participant was instructed to perform five warm-up
repetitions. Next, a starting weight was selected and each participant was asked to
perform repetitions until told to stop. If a participant reached ten repetitions, the set was
stopped automatically. An RPE was asked of the participant after every set and then the
weight was adjusted accordingly. If ten repetitions were reached during the second set,
the participant would move on to another machine and then repeat the same machine later
during the assessment.
Handgrip Strength Assessment. Handgrip strength was evaluated using a
handgrip dynamometer (Takei Scientific Instruments Co., LTD., Niigata City, Japan).
The handgrip size was adjusted accordingly for the participant. The participant was then
instructed to hold the dynamometer by his or her side with the dial facing away from the
body, and to squeeze the dynamometer as hard as possible without moving the arm.
Three trials were administered for each hand, alternating hands after every attempt, and
then the highest values were recorded.
Core Muscular Endurance Assessment. Core muscular endurance was assessed
using the plank test. For the plank test, the participant began in a neutral position on his
or her hands and knees. Each participant was then instructed to assume the plank
position, with his or her forearms on the floor in front of him or her, while keeping his or
her hips in line with his or her spine and were asked to hold the position as long as
possible to a maximum of 60 seconds. The time was recorded and a score was assigned.
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Chair Squat Test. For the chair squat test, the researchers showed the participant
the proper form for doing a squat onto a chair. A chair was then positioned behind the
participant and the participant was instructed to cross his or her arms and squat down into
the chair so that their buttocks touched the seat for a brief moment, and then return to
standing. The participant was instructed to perform as many squats as possible until
fatigue or until 50 repetitions were completed. Values were then recorded.
Chemotherapy-Induced Peripheral
Neuropathy Assessment
Chemotherapy-Induced Peripheral Neuropathy (CIPN) was evaluated in each
participant to look for changes prior to and after the 12-week intervention of strength,
aerobic and flexibility training. CIPN was evaluated using the Semmes-Weinstein
Monofilament Test (SWMT) (Feng, Schlösser, & Sumpio, 2011; Tan, 2010; Feng et al.,
2009; Kamei et al., 2005; Leonard et al., 2004; Lee et al., 2003; Kochman et al., 2002;
Olaleye et al., 2001; Mueller, 1996; Kumar et al., 1991; Grunfield, 1988). A total of ten
sites were evaluated using the 5.07/10g monofilament and the 4.17/1 monofilament on
both the feet and hands of the participant, depending on the location of the neuropathy.
The ten sites used to assess the foot were the dorsal mid-foot, the medial and lateral midfoot, the calcaneus, and the plantar aspect of the foot, including the first, third, and fifth
digits, as well as the first, third, and fifth metatarsal heads (Figure 1). Both the 4.17 and
5.07 monofilament have been suggested to be used to identify patients at risk with
peripheral neuropathy (Lee et al., 2003; Mueller, 1996; Kumar et al., 1991). The tests
were performed bilaterally. Participants who had self-reported symptoms of CIPN in the
feet were instructed to lie supine, with their toes pointing up, and were blindfolded. The
researcher instructed the participant to say “yes” when the participant felt the
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monofilament. The researcher did not inform the participant when the monofilament
would be applied to the skin and the sites were randomly tested. The filament was
pressed slowly onto the test site and then bowed for 1.5 seconds. The participant was
instructed to respond, “Yes,” whenever the participant recognized that he or she was
being touched by the filament and on which side of the body. Participants who could not
detect the 4.17 or 5.07 monofilament on a specific site were classified as having a loss of
protective sensation in that specific site. To assess for neuropathy of the hand, a ten-site
method was used. The sites were: (1) the medial surface of the palm, (2) first medial
metacarpal head, (3-5) first, third, and fifth metacarpophalangeal joint, (6-8) first, third,
and fifth distal phalanx head, and (9-10) the third and fifth distal metacarpal head (Van
Brakel et al., 2003; Nunes, de Oliveira, Aruin, & dos Santos, 2012). (Figure 2). The same
monofilaments were used for the hand test as for the foot test. For this test, the participant
was instructed to lie supine, extend his or her arm out laterally, palm face up, and were
blindfolded. Participants were also blinded to the test in that they were not able to watch
the test being performed on them. The test would then be administered the same way as
the foot assessment and one insensate site would put the participant at risk for neuropathy
(Tan, 2010). Quick application and bouncing of the filament were avoided. To help
ensure accuracy, the same two evaluators were used for every SWMT test. Using a
conservative approach for this study, it was best thought to include a site pertaining to
each nerve that runs through either the hand or foot. Also, because there is no clear
evidence on how to score a SWMT, any one insensate site was considered to be an
indication of neuropathy (Tan, 2010).
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Phase Training of Cancer Rehabilitation
The exercise intervention took place at the Rocky Mountain Cancer Rehabilitation
Institute (RMCRI) on the University of Northern Colorado (UNC) campus in Greeley,
Colorado. RMCRI is a nationally recognized cancer rehabilitation center that maintains
consistent referrals of cancer patients who experience treatment-related side effects.
Physiological data was recorded by UNC graduate and undergraduate students in the
exercise physiology department. RMCRI utilizes a Phase training system to confirm that
the five basic principles of exercise are being met. These five principles include overload,
specificity, individuality, diminishing return, and reversibility. The Phase system allows
for individuality of each participant based on stage of cancer, treatment types, and time
since treatment. It also allows for progression at appropriate intensities according to the
individual.
The RMCRI phase program consists of four Phases. Phase One consists of
participants who are receiving treatment during the exercise intervention. The main goal
of this Phase is to attenuate the deleterious effects of chemotherapy and radiation
treatments. The participants who are in this Phase may not see improvement, but there
should not be any declination in initial values. The exercise intensity established for this
phase is 30-45% of a participant’s heart rate reserve (HRR) and est. 1-RM.
Cardiovascular and muscular improvement might only be 0-5% for this phase, and
participants should be reporting RPE values from 1-3. The participant remains in Phase
One until he or she has fully completed his or her treatment regimen.
Phase Two of the training program is intended for participants who have
graduated from Phase One, participants who have had only surgical and/or hormonal
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treatment, or participants who are new to the RMCRI program and have not undergone
chemotherapy or radiation. The goal of Phase Two is to build a foundational base of
exercise using corrective and functional training. The training intensity established for
this phase is 40%-60% of the participant’s HRR and est. 1-RM, and the participant
should be reporting RPE’s of 3-6. Cardiovascular and muscular improvement for this
Phase may increase by 10-20%. The time duration of this phase is 12 weeks.
Phase Three of RMCRI’s phase training program is intended for participants who
have graduated from Phase Two. The goal of this phase is to continue to improve
physiological and psychological variables beyond baseline measures and should be able
to progress to functional health or become “apparently healthy.” Another goal of this
Phase is to instruct the participant how to exercise without the help of a trainer and for
the participant to become knowledgeable about exercises. The exercise intensity
established for this phase is considered moderate-to-high at 60%-85% of the participant’s
HRR and est. 1-RM. Cardiovascular improvements may increase by 5-15% for this
phase, while muscular improvements may improve by 30-50%. The period for this Phase
is three months.
Phase Four of RMCRI’s phase program is for participants who have graduated
from Phase Three and could be considered “apparently healthy.” The goal of this phase
is to continue improving physiological and psychological measures. The exercise
intensity established for this phase is 65%-95% of a participant’s HRR and est. 1-RM,
and the timeline is limitless for this Phase. Clients who are in this Phase are now healthy
and knowledgeable enough to exercise on their own, in a group model, or continue with
one-on-one training. Cardiovascular and muscular improvements should be greater than
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5% increments for this phase. For the purpose of this study, only participants in Phases
One and Two will be used.
	
  

Exercise Intervention
The aerobic portion of the intervention was conducted on a treadmill

(Trackmaster, city etc. or MedTrack CR60, city etc.), cycle ergometer (Life Cycle 8500,
city etc.; Life Cycle 9500E, city etc.; SciFit, city), and/or NuStep (Biodex), Aerobic
exercise was performed for 20 minutes between 30% and 60% of the participant’s HRR
depending on the Phase of the RMCRI program the participant was enrolled into. Each
participant was prescribed to either maintain his or her cardiovascular and muscular
strength baseline measures or increase from 5%-20% also depending on his or her phase.
The muscular strength portion of the intervention was conducted with free
weights, Cybex Fitness Machines, and/or body weight. The muscular strength
intervention was also performed at 30% to 60% of the participant’s est. 1-RM depending
on the Phase of the RMCRI program the participant was assigned. The participant either
maintained muscular strength or increased it by 10%-50%. This portion of the
intervention lasted 30 minutes. During the muscular strength training intervention,
balance was also included. In order to incorporate balance, the participant may have been
asked to perform an exercise on a stability ball, BOSU, foam pad, or textured balance
pods.
The flexibility portion of the intervention lasted ten minutes in length and was
conducted at the end of the training session. Any muscle groups used during the strength
portion of the training intervention were stretched accordingly and ranges of motion
stretches were included. Stretches were also done in accordance with the participant’s
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NASM squat test results. Equipment that may have been used for stretching included
rope pulleys, a ROM wheel harnessed to the wall, ropes, or gliding disks.
	
  

Statistical Analysis
Preliminary descriptive and data frequency analyses were run to represent the raw

data visually. A power analysis was run initially to determine appropriate sample size. A
Wilk’s Lambda multivariate analysis of variance (MANOVA) test was run on the pre,
mid, and post CIPN assessment scores to evaluate any changes due to the exercise
intervention. Individual MANOVA’s were run for the 4.17 and 5.07 monofilament tests.
A paired sample T-test was run on physiological assessment pre- and post- data and
psychological assessment data to evaluate any changes due to the exercise intervention.
Data was analyzed using statistical software (SPSS, 20). Significance was set at p < 0.05.
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CHAPTER IV

RESULTS
Participant Characteristics

	
  

Participant characteristics are shown in Table 1. For the purpose of this
observation, this study included 10 participants (6 females, 4 males). Ten out of thirteen
eligible participants completed the 12-week exercise intervention along with pre-, mid-,
and post- assessments. Two subjects that were not able to complete the study dropped out
for personal reasons and one subject passed away during the study. Each participant that
completed the training study was able to complete 36 sessions. If a participant had to
cancel a session for personal reasons, there were no more than 10 days between the next
training sessions in order to sustain training effects. All participants completed pre-, midand post- assessments. Cancer Exercise Specialists at the Rocky Mountain Cancer
Rehabilitation Institute conducted the physical and psychological assessments. In
addition, during the year and a half that this study took place, there were a total of two
different assessors for the CIPN portion of the assessment.
Table 1
Participant Characteristics
N
Weight (pounds)
Height (inches)
Age (years)
12
171 ± 46
66 ± 4
62 ± 7
Note: Values are means ± standard deviation; N, number of participants
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Chemotherapy-Induced Peripheral Neuropathy
Changes after Intervention
The Wilk’s Lambda Multivariate Test showed significant (P < .05) effects
between all three levels for the 4.17 SWMT. Mauchly’s test of sphericity did not show
significance (p > .05) of variance between groups. Results are presented in Table 2
below. Figure 1 also shows a negative trend of the SWMT 4.17 cumulative scores over
time. For the 5.07 SWMT, the Wilks Lambda Multivariate test showed no significant
effects (p > .05) due to training. Mauchly’s test of sphericity did not show significance (p
< .05) of variance between groups. Statistical results are presented in Table 2 below.
Figure 2 shows a partial negative trend of SWMT 5.07 cumulative scores below.

Table 2
SWMT Significant Differences
p value

Mauchly’s Test
of Sphericity
SWMT 4.17
.025
.576
SWMT 5.07
.060
.957
Note: Significant difference for SWMT 4.17 pre- to mid- to post; no significant
differences were found for SWMT 5.07 tests pre- to mid- to post-; SWMT, Semmes
Weinstein Monofilament Test; *significantly different at p < .05.
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Figure 1. 4.17 Semmes Weinstein Monofilament Scores Over Time. Values are
composite scores from each participant; Average, average score on CIPN assessment;
linear trend line is based on average scores; CIPN, chemotherapy-induced peripheral
neuropathy;
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Figure 2. 5.07 Semmes Weinstein Monofilament Scores Over Time. Values are
composite scores from each participant; Average, average score on CIPN assessment;
linear trend line is based on average scores; CIPN, chemotherapy-induced peripheral
neuropathy;
Strength Changes after Exercise
Intervention
Paired Sample T-Tests showed some significant (p < .05) changes in strength pre
to post assessment. Results for all strength assessments pre- to post are presented in Table
3 below. Latissimus pull-down, shoulder press, chest press, leg curl, and leg press all
showed significant changes. Row and leg extension did not show significant changes.
Functional strength showed some significant (p < .05) changes in strength pre to post.
Results for functional strength assessments pre- to post- are presented in Table 4 below.
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Both right and left hand grip tests showed significant changes; however, the chair test and
plank test did not show significant changes.
Table 3
Strength Vales Pre- and Post- Intervention
Exercise

Pre
(pounds)
89 ± 35

Post
(pounds)
100 ± 28

p value

Latissimus Pull
.021*
down
Shoulder Press
40 ± 19
54 ± 23
.014*
Chest Press
64 ± 28
84 ± 38
.000*
Row
71 ± 26
92 ± 34
.141
Leg Curl
79 ± 28
99 ± 23
.030*
Leg Extension
83 ± 41
111 ± 46
.085
Leg Press
158 ± 45
206 ± 64
.002*
Note: Weights are means ± standard deviation in pounds; *significance set at p < .05.
Table 4
Functional Strength Values Pre- and Post- Intervention
Exercise
Pre
Post
p value
Chair Test (reps)
20 ± 14
28 reps ± 10
.148
Plank Test (reps)
41 ± 23
48 sec ± 20
.450
Handgrip R (kg)
22 ± 10
27 kg ± 12
.000*
Handgrip L (kg)
21 ± 11
24 kg ± 11
.003*
Note: Values are means ± standard deviation; Reps, repetitions; sec, seconds; kg,
kilograms; *significantly different at p < .05.
Aerobic Changes after Exercise Intervention
There were significant (p < .05) main effects observed for Paired T-Test analysis
for VO2peak . Aerobic physiological changes from pre- to post- training assessments are
displayed in Table 5.
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Table 5
VO2peak Pre- and Post- Intervention

VO2peak

Pre

Post

p value

19.07 ± 3.4

24.1 ± 7.7

.014*

Note: All values are ml/kg/min-1; Values are means + standard deviation; *significantly
different at p < .05.
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CHAPTER V

DISCUSSION
	
  
The Wilk’s Lambda Multivariate test was able to also show significant
differences between pre- and post- data for VO2peak, strength values, and functional
strength values. It was expected that significant differences would be present between the
pre and post assessments. In fact, VO2peak increased significantly due to the aerobic
exercise intervention. All strength values increased significantly with the exception of
the 1-RM row, 1-RM leg extension, chair squat test, and plank test. This indicates that
exercise adaptations did occur and the reduction in CIPN symptoms could be related to
the exercise adaptations. It could also be concluded from the results that exercise had a
beneficial effect on CIPN symptoms. Research has supported the assumption that
exercise stimulates endoneurial blood flow and mitochondrial protein synthesis and
glycolysis which both have the ability to generate energy (Tofthagen et al., 2012).
Exercise could ultimately increase the supply of blood, oxygen, and other essential
nutrients to the mitochondria, and then to the peripheral nerves, which could result in
fewer neuropathic symptoms (Tofthagen et al., 2012). Exercise also has been suggested
to enhance nerve re-innervation as well as an increase in neurotropic factors within the
peripheral nerves (Wilkes, 2007; Sabatier et al., 2008). Both of these have the possibility
of regenerating nerve endings, and the current study suggests that these theories may
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possibly be accurate. In addition, the theory that exercise can benefit peripheral nerve
damage is in agreement with Sabatier et al., 2008 and Kluding et. al., 2012.
The reduction in 4.17 SWMT scores from pre- to post- and symptoms supports
the theory that exercise could serve as an alternative form of treatment in the
management of CIPN. However, it is unknown from this study whether or not the
aerobic exercise, strength training, or combination of the two was more beneficial. Since
both aerobic and strength training have been shown to improve side effects of cancer
treatments, the researchers did not want to disadvantage any participants by only having
them participate in one modality. Further research will need to be conducted to determine
if one modality has a greater effect than the other on CIPN symptoms. However, for the
purpose of this study, the combination of the two suggested the greatest benefit in
reduction of CIPN symptoms.
Future research should also include analyzing different modalities that could
increase blood flow and peripheral vasodilation to the nerves, such as laser treatments or
heat treatments. However, patients who experience CIPN can have difficulty in sensing
temperature in the affected areas (Wolf et al., 2008; Wilkes, 2007). Some subjects may
sense temperatures as extremes, and some subjects may not feel any temperature change
at all. What would be warm to an apparently healthy person may present as a burning
sensation to a person experiencing CIPN. Also, if the temperature is too hot, the subject
may not be able to sense that it is too hot. Thus, temperature would have to be closely
monitored.
Another explanation to the reduction in 4.17/1g SWMT scores is a cessation of
treatment. All of the subjects were no longer receiving their chemotherapy treatments. As
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stated earlier, CIPN is dose dependent, indicating that once a subject stops receiving
treatment, his or her symptoms may disappear. This is not always the case, however, as
each subject is different. In order to control for this, future research will need to include a
control group.
`

The Wilk’s Lambda Multivariate test was able to show significant differences

between pre-, mid-, and post- CIPN assessment scores for the 4.17/1g SWMT but not for
the 5.07/10g SWMT. These two tests differ in that the 4.17/1g SWMT is used to detect a
diminishing protective sensation and the 5.07/10g SWMT is used to detect the loss of
protective sensation (Feng et al., 2009; Tan, 2010; Lee et al., 2003; Olaleye et al., 2001;
Kamei et al., 2005; Leonard et al., 2004; Kumar et al., 1991; Lee et al., 2003; Callahan et
al., 1995; Kumar et al., 1991). Thus, the 4.17/1g SWMT detects for the onset of
neuropathy, while the 5.07/10g SWMT detects for a more progressive form of
neuropathy. Paresthesia and numbness are sometimes considered earlier signs of
neuropathy because the sensory neurons and axons that transmit these signals are
unmyelinated, so they are affected sooner than myelinated fibers by the chemotherapy
agents (Malik & Stillman, 2008). As CIPN progresses, all sensation would cease in the
hands and feet (Malik & Stillman, 2008). This could suggest that the subjects from this
study were still in the early stages of CIPN, which would indicate why the 5.07/10g
SWMT did not significantly report changes in CIPN. The 4.17/1g SWMT may be more
useful in the early detection of peripheral neuropathy and may be more useful for
detecting CIPN. All of the subjects had patient reported symptoms of CIPN prior to entry
into the study. However, some subjects were still sensate to the 5.07/10g SWMT, but
were insensate to the 4.17/1g SWMT. It is possible that some patients with CIPN did not
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have complete loss of protective sensation; thus, they could still feel the 5.07/10g
SWMT. Thus, if a patient reports he or she is feeling signs of neuropathy, it is possible he
or she would still be sensate to the 5.07/10g monofilament. It could conclude that all the
subjects were only experiencing a diminished loss of protective sensation and CIPN is
more likely to be diminishing in sensation rather than a total loss of protective sensation.
This could also conclude that 4.17g/1g monofilament is a more accurate measurement for
CIPN because it tests for the diminished sensation rather than total loss.
The 5.07/10g SWMT test did not present with significant differences from pre- to
mid- to post- CIPN assessment scores. This could be mainly due to the fact that current
research supports the 5.07/10g SWMT for diabetic peripheral neuropathy, but not for
CIPN. Since the cellular mechanisms between the two conditions are different, the caliber
of symptoms may also be different. The general symptoms between the two are similar;
however, DPN is speculated to be caused by a metabolic issue, while CIPN is said to be
caused by toxic agents (Schloss et al., 2013; Kluding et al., 2012; Wolf et al., 2008;
Balducci et al., 2006). The results from the current study are not in agreement with
current research (Feng et al., 2009; Tan, 2010; Lee et al., 2003; Olaleye et al., 2001;
Kumar et al., 1991). However, many of these studies were assessing the use of the
5.07/10g SWMT on diabetic peripheral neuropathy. The 5.07/10g SWMT may not be a
useful assessment tool for CIPN and needs further research. DPN is due to a
hyperglycemic environment, ultimately (Head, 2006). DPN can be possibly resolved by
maintaining glycemic control (Singh, Armstrong, & Lipsky, 2005; Kluding et al., 2012;
Braunstein, 2001). CIPN is due to a toxic agent damaging part of the nerve and
impairment in the repair mechanisms (Head, 2006). CIPN can be reversible over time
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(Quasthoff & Hartung 2002). Currently, the only alleviating agent for CIPN is cessation
of chemotherapy treatment (Hausheer et al., 2006; Quasthoff & Hartung 2002; Wilkes,
2007). However, this is not always an option for many people who are receiving
chemotherapy. Some studies have found vitamins to be helpful, but nothing that
demonstrated substantial efficacy (Hausheer et al., 2006; Quasthoff & Hartung 2002;
Speck et al., 2012). The results from the current study suggest that exercise could be
beneficial in alleviating symptoms of CIPN.
The results of this study indicate that exercise may an effective and safe treatment
in the management of CIPN symptoms. Prior research has examined the effects of
vitamins on CIPN symptoms, but no conclusive results were obtained. Heat therapy could
also be beneficial for patients with CIPN; however, there is a higher risk factor for burns
or injury due to the nature of the symptoms of CIPN. Not only could exercise alleviate
CIPN symptoms, but it has shown improvement for other side effects that could develop
due to chemotherapy treatments as well.
Conclusion
To our knowledge, there has been very little research on the effects of aerobic
training and strength training on CIPN symptoms. Results from the current study reported
significant differences between pre-, mid-, and post- 4.17 SWMT CIPN assessment
scores, as well as other important outcomes occurred. First, aerobic and strength training
were beneficial to paresthesia symptoms associated with CIPN. Exercise has the ability to
increase blood flow and nutrient flow to peripheral nerves, which could help repair any
damage that occurred (Tofthagen et al., 2012; Sabatier et al., 2008; Wilkes, 2007;
Kluding et al., 2012). Second, the 4.17/1g SWMT may be a more appropriate instrument
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for assessing neuropathy in cancer patients than other calibers of the SWMT. All of the
subjects assessed had patient-reported symptoms of neuropathy; however, the 5.07/10g
SWMT, which previous research supported, did not significantly detect changes in CIPN
score. More research and validation is needed for this theory. Lastly, exercise should be
included in any post-cancer treatment rehab because it can attenuate many side effects of
treatment. Along with being beneficial for the symptom management of CIPN, it can also
lessen fatigue and depression, increase VO2peak, and increase whole body strength.
Previous studies have documented exercise as beneficial to anyone who is combating
cancer treatments, but to date, there is not much research examining the effects of aerobic
and strength training on CIPN.
	
  

Limitations
Although the need for more research in this area was a strong point for this study,

several limitations did occur. The small sample size was a major limitation to this study.
The original power analysis suggested a sample size of fifteen participants. However, due
to Cancer Exercise Specialist availability and scheduling, RMCRI was not able to accept
as many new patients as preferred. Time frame was also a limitation to this study. CIPN
was only assessed over a 12-week period. Many participants still had some symptoms of
CIPN at the end of their intervention. A major limitation to this study was the lack of a
control group. Since research has shown to benefit patients who are receiving cancer
treatment, the researchers did not want to disadvantage some in order to create a control
group. It is also known that CIPN is dose-dependent. This means that if a subject were to
terminate his or her chemotherapy, it is possible that CIPN symptoms would start to
disappear without the help of an exercise protocol. Future research will need to include a
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control group to test for this assumption. A longer time period is needed to further
evaluate the effects of exercise. Along with time frame, another limitation is when the
patient stopped receiving his or her chemotherapy treatment. Since CIPN is dose
dependent, it is possible that a patient’s symptoms will gradually start to lessen after he or
she receives his or her final dose of chemotherapy. Another major limitation was the lack
of knowledge. There is very little research regarding CIPN and exercise to date. Due to
this, researchers had to rely on information regarding diabetic peripheral neuropathy.
However, the two conditions are similar, but the mechanism of onset is different; thus,
treatment and management may be different as well. More research needs to be
conducted within this area of cancer research.

	
  

36

REFERENCES
American Cancer Society. (2015). Cancer Facts & Figures. Atlanta, GA: American
Cancer Society.
Arena, R. (2014). Exercise testing. In L. Pescatello (Ed.), ACSM's guidelines for exercise
testing and prescription (9th ed., pp. 60-75). Baltimore, MD: Lippincott Williams
& Wilkins.
Argyriou, A. A., Bruna, J., Marmiroli, P., & Cavaletti, G. (2012). Chemotherapy-induced
peripheral neurotoxicity (CIPN): an update. Critical Reviews in
Oncology/Hematology, 82(1), 51-77.
Balducci, S., Iacobellis, G., Parisi, L., Di Biase, N., Calandriello, E., Leonetti, F., &
Fallucca, F. (2006). Exercise training can modify the natural history of diabetic
peripheral neuropathy. Journal of Diabetes and its Complications, 20(4), 216223.
Braunstein, J. B. (2001). Exercise and Neuropathy. Diabetes Forecast, 54(8), 38-41.
Brzycki, M. (1993). Strength testing—predicting a one-rep max from reps-to-fatigue.
Journal of Physical Education, Recreation & Dance, 64(1), 88-90.
Callahan, A. D., Hunter, J. M., & Mackin, E. (1995). Rehabilitation of the Hand: Surgery
and Therapy. Mosby.
Feng, Y., Schlösser, F. J., & Sumpio, B. E. (2009). The Semmes Weinstein monofilament
examination as a screening tool for diabetic peripheral neuropathy. Journal of
Vascular Surgery, 50(3), 675-682.
	
  

37
Feng, Y., Schlösser, F. J., & Sumpio, B. E. (2011). The Semmes Weinstein monofilament
examination is a significant predictor of the risk of foot ulceration and amputation
in patients with diabetes mellitus. Journal of Vascular Surgery, 53(1), 220-226.
Ferrans, C.E., & Powers, M.J. (1985). Quality of life index: development and
psychometric properties. Advances in Nursing Science, 8(1), 15-24.
Grunfeld, C. (1988). Aesthesiometry: quantification of cutaneous pressure sensation in
diabetic peripheral neuropathy. Journal of Rehabilitation Research and
Development, 25(2).
Hausheer, F. H., Schilsky, R. L., Bain, S., Berghorn, E. J., & Lieberman, F. (2006,
February). Diagnosis, management, and evaluation of chemotherapy-induced
peripheral neuropathy. In Seminars in Oncology (Vol. 33, No. 1, pp. 15-49). WB
Saunders.
Head, K. A. (2006). Peripheral neuropathy: pathogenic mechanisms and alternative
therapies. Alternative Medicine Review, 11(4), 294.
Hsieh, C., Sprod, L.K., Hydock, D.S., Carter, S.D., Hayward, R., & Schneider, C.M.
(2008). Effects of a supervised exercise intervention on recovery from treatment
regimens in breast cancer survivors. Oncology Nursing Forum, 35(6), 909-915.
NIH Public Access.
Kamei, N., Yamane, K., Nakanishi, S., Yamashita, Y., Tamura, T., Ohshita, K., ... &
Kohno, N. (2005). Effectiveness of Semmes–Weinstein monofilament
examination for diabetic peripheral neuropathy screening. Journal of Diabetes
and its Complications, 19(1), 47-53.

	
  

38
Kluding, P. M., Pasnoor, M., Singh, R., Jernigan, S., Farmer, K., Rucker, J., ... & Wright,
D. E. (2012). The effect of exercise on neuropathic symptoms, nerve function,
and cutaneous innervation in people with diabetic peripheral neuropathy. Journal
of Diabetes and its Complications, 26(5), 424-429.
Kochman, A. B., Carnegie, D. H., & Burke, T. J. (2002). Symptomatic reversal of
peripheral neuropathy in patients with diabetes. Journal of the American
Podiatric Medical Association, 92(3), 125-130.
Kumar, S., Fernando, D. J. S., Veves, A., Knowles, E. A., Young, M. J., & Boulton, A. J.
M. (1991). Semmes-Weinstein monofilaments: a simple, effective and
inexpensive screening device for identifying diabetic patients at risk of foot
ulceration. Diabetes Research and Clinical Practice, 13(1), 63-67.
Lee, S., Kim, H., Choi, S., Park, Y., Kim, Y., & Cho, B. (2003). Clinical usefulness of
the two-site Semmes-Weinstein monofilament test for detecting diabetic
peripheral neuropathy. Journal of Korean Medical Science, 18(1), 103.
Leonard, D. R., Farooqi, M. H., & Myers, S. (2004). Restoration of Sensation, Reduced
Pain, and Improved Balance in Subjects With Diabetic Peripheral Neuropathy A
double-blind, randomized, placebo-controlled study with monochromatic nearinfrared treatment. Diabetes Care, 27(1), 168-172.
Malik, B., & Stillman, M. (2008). Chemotherapy-induced peripheral neuropathy. Current
Neurology and Neuroscience Reports, 8(1), 56-65.
Mathiowetz, V., Weber, K., Volland, G., & Kashman, N. (1984). Reliability and validity
of grip and pinch strength evaluations. The Journal of Hand Surgery, 9(2), 222226.

	
  

39
Mueller, M. J. (1996). Identifying patients with diabetes mellitus who are at risk for
lower-extremity complications: use of Semmes-Weinstein monofilaments.
Physical Therapy, 76(1), 68-71.
Nunes, P. M., de Oliveira, D. G., Aruin, A. S., & dos Santos, M. J. (2012). Relationship
between hand function and grip force control in women with hand osteoarthritis.
Journal of Rehabilitation Research and Development, 49(6), 855-866.
Ohrvall, M., Berglund, L., & Vessby, B. (2000). Sagittal abdominal diameter compared
with other anthropometric measurements in relation to cardiovascular risk.
International Journal of Obesity and Related Metabolic Disorders: Journal of the
International Association for the Study of Obesity, 24(4), 497-501.
Olaleye, D., Perkins, B. A., & Bril, V. (2001). Evaluation of three screening tests and a
risk assessment model for diagnosing peripheral neuropathy in the diabetes clinic.
Diabetes Research and Clinical Practice, 54(2), 115-128.
Persohn, E., Canta, A., Schoepfer, S., Traebert, M., Mueller, L., Gilardini, A., ... &
Cavaletti, G. (2005). Morphological and morphometric analysis of paclitaxel and
docetaxel-induced peripheral neuropathy in rats. European Journal of Cancer,
41(10), 1460-1466.
Pignataro, R. M., & Swisher, A. K. (2010). Chemotherapy induced peripheral
neuropathy: risk factors, pathophysiology, assessment, and potential physical
therapy interventions. Rehabilitation Oncology, 28(2), 10.
Piper, B. F., Dibble, S.L., Dodd, M. J., Weiss, M. C., Slaughter, R.E., & Paul, S.M.
(1998). The revised Piper Fatigue Scale: psychometric evaluation in women with
breast cancer. Oncology Nursing Forum, 25(4), 677-684.

	
  

40
Quasthoff, S., & Hartung, H. P. (2002). Chemotherapy-induced peripheral neuropathy.
Journal of Neurology, 249(1), 9-17.
Rikli, R. E., & Jones, C. J. (1999). Development and validation of a functional fitness test
for community-residing older adults. Journal of Aging and Physical Activity, 7,
129-161.
Sabatier, M. J., Redmon, N., Schwartz, G., & English, A. W. (2008). Treadmill training
promotes axon regeneration in injured peripheral nerves. Experimental
Neurology, 211(2), 489-493.
Salkind, K.H. (1969). Beck depression inventory in general practice. Journal of the Royal
College of General Practice, 18(88), 267-271.
Schloss, J. M., Colosimo, M., Airey, C., Masci, P. P., Linnane, A. W., & Vitetta, L.
(2013). Nutraceuticals and chemotherapy induced peripheral neuropathy (CIPN):
a systematic review. Clinical Nutrition, 32(6), 888-893.
Schloss, J., Colosimo, M., Airey, C., Masci, P. P., Linnane, A. W., & Vitetta, L. (2014,
October). B complex vitamins reduce the onset and severity of chemotherapy
induced sensory peripheral neuropathy. In Conference and Exhibition on
Nutraceuticals and Functional Foods.
Schneider, C. M., Dennehy, C. A., & Carter, S. D. (2003). Exercise and Cancer
Recovery. Human Kinetics.
Schneider, C.M., Hsieh, C.C., Sprod, L.K., Carter, S.D., & Hayward, R. (2007a). Cancer
treatment-induced alterations in muscular fitness and quality of life: the role of
exercise training. Annals of Oncology, 18(12). 1957-1962.
Schneider, C. M., Hsieh, C. C., Sprod, L. K., Carter, S. D., & Hayward, R. (2007b).

	
  

41
Effects of supervised exercise training on cardiopulmonary function and fatigue in
breast cancer survivors during and after treatment. Cancer, 110(4), 918-925.
Shackelford, D. Y., Brown, J. M., Lalonde, T. L., Hydock, D. S., & Schneider, C. M.
(2012). Validation of the Rocky Mountain Cancer Rehabilitation Institute
Multistage Treadmill Protocol for Cancer Survivors. In Medicine and Science in
Sports and Exercise (Vol. 44, pp. 751-751). 530 Walnut St., Philadelphia, PA
19106-3621 USA: Lippincott Williams & Wilkins.
Singh, N., Armstrong, D. G., & Lipsky, B. A. (2005). Preventing foot ulcers in patients
with diabetes. Jama, 293(2), 217-228.
Speck, R. M., DeMichele, A., Farrar, J. T., Hennessy, S., Mao, J. J., Stineman, M. G., &
Barg, F. K. (2012). Scope of symptoms and self-management strategies for
chemotherapy-induced peripheral neuropathy in breast cancer patients. Supportive
Care in Cancer, 20(10), 2433-2439.
Tan, L. S. (2010). The clinical use of the 10g monofilament and its limitations: a review.
Diabetes Research and Clinical Practice, 90(1), 1-7.
Tofthagen, C., Visovsky, C., & Berry, D. L. (2012, September). Strength and balance
training for adults with peripheral neuropathy and high risk of fall: current
evidence and implications for future research. In Oncology Nursing Forum (Vol.
39, No. 5, pp. E416-24).
Tortora, G. J., & Derrickson, B. H. (2009). Principles of Anatomy and Physiology:
Organization, Support and Movement and Control Systems of the Human Body.
Hoboken, NJ: John Wiley and Sons.

	
  

42
Van Brakel, W. H., Anderson, A. M., Withington, S. G., Croft, R. P., Nicholls, P. G.,
Richardus, J. H., & Smith, W. C. S. (2003). The prognostic importance of
detecting mild sensory impairment in leprosy: a randomized controlled trial
(TRIPOD 2). Leprosy Review, 74(4), 300-310.
Wickham, R. (2007). Chemotherapy-induced peripheral neuropathy: a review and
implications for oncology nursing practice. Clinical Journal of Oncology Nursing,
11(3), 361.
Widmaier, E. P., Raff, H., & Strang, K. T. (2006). Vander’s human physiology: the
mechanisms of human body function. 10th ed.
Wilkes, G. (2007). Peripheral neuropathy related to chemotherapy. Seminars In Oncology
Nursing, 23(3), 162-173 12p.
Wolf, S., Barton, D., Kottschade, L., Grothey, A., & Loprinzi, C. (2008). Chemotherapyinduced peripheral neuropathy: prevention and treatment strategies. European
Journal of Cancer, 44(11), 1507-1515.

	
  

43

APPENDIX A
INSTITUTIONAL REVIEW
BOARD APPROVAL

	
  

44

Institutional Review Board
DATE:

March 31, 2015

TO:
FROM:

Reid Hayward, PhD
University of Northern Colorado (UNCO) IRB

PROJECT TITLE:
SUBMISSION TYPE:

[573297-3] Exercise Interventions to Attenuate the Negative Side-Effects of
Cancer Treatments
Continuing Review/Progress Report

ACTION:
APPROVAL DATE:
EXPIRATION DATE:
REVIEW TYPE:

APPROVED
March 27, 2015
March 27, 2016
Expedited Review

Thank you for your submission of Continuing Review/Progress Report materials for this project. The
University of Northern Colorado (UNCO) IRB has APPROVED your submission. All research must be
conducted in accordance with this approved submission.
This submission has received Expedited Review based on applicable federal regulations.
Please remember that informed consent is a process beginning with a description of the project and
insurance of participant understanding. Informed consent must continue throughout the project via
a dialogue between the researcher and research participant. Federal regulations require that each
participant receives a copy of the consent document.
Please note that any revision to previously approved materials must be approved by this committee prior
to initiation. Please use the appropriate revision forms for this procedure.
All UNANTICIPATED PROBLEMS involving risks to subjects or others and SERIOUS and UNEXPECTED
adverse events must be reported promptly to this office.
All NON-COMPLIANCE issues or COMPLAINTS regarding this project must be reported promptly to this
office.
Based on the risks, this project requires continuing review by this committee on an annual basis. Please
use the appropriate forms for this procedure. Your documentation for continuing review must be received
with sufficient time for review and continued approval before the expiration date of March 27, 2016.
Please note that all research records must be retained for a minimum of three years after the completion
of the project.
If you have any questions, please contact Sherry May at 970-351-1910 or Sherry.May@unco.edu. Please
include your project title and reference number in all correspondence with this committee.

-1-

	
  

Generated on IRBNet

45

Dr. Hayward and colleagues Thank you for the clear and thorough IRB continuation review application. Please add a place for
participants to initial the first page of the two-page consent form (i.e., Page 1 of 2 ______ please
initial) given that the signatures are on page 2 per IRB guidelines. This small revision does not
need to be submitted for subsequent review.
Best wishes with your continued, valuable research at the Rocky Mountain Cancer Rehabilitation
Institute and please don't ever hesitate to contact me with any IRB-related questions or concerns.
Sincerely,
Dr. Megan Stellino, UNC IRB Co-Chair

This letter has been electronically signed in accordance with all applicable regulations, and a copy is retained within University of
Northern Colorado (UNCO) IRB's records.

-2-

	
  

Generated on IRBNet

46

APPENDIX B
INFORMED CONSENT

	
  

47

	
  

48
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Stage

	
  

Speed
(mph)

Grade
(%)

Time
Corresponding
with VO2 Peak
Calculation

Estimated VO2 Peak
(mL/kg/min)

Estimated VO2 Peak (Handrails)

0

1.0

0

1:00-1:59

6.2 (walk)

6.2 (walk)

1

1.5

0

2:00-2:59

7.5 (walk)

7.5 (walk)

2

2.0

0

3:00-3:59

8.9 (walk)

8.9 (walk)

3

2.5

0

4:00-4:59

10.2 (walk)

10.2 (walk)

4

2.5

2

5:00-5:59

12.6 (walk)

12.1 (walk)

5

3.0

2

6:00-6:59

14.4 (walk)

13.4 (walk)

6

3.3

3

7:00-7:59

17.1 (walk)

15.2 (walk)

7

3.4

4

8:00-8:59

19.2(walk)

16.6 (walk)

8

3.5

5

9:00-9:59

21.3(walk)

18.1 (walk)

9

3.6

6

10:00-10:59

28.0 (run)

23.6 (walk)

22.8 (run)

19.7 (walk)

10

3.7

7

11:00-11:59

29.6 (run)

25.9 (walk)

23.9 (run)

21.3 (walk)

11

3.8

8

12:00-12:59

31.2 (run)

28.3 (walk)

25.0 (run)

23.0 (walk)

12

3.9

9

13:00-13:59

32.9 (run)

30.9 (walk)

26.1 (run)

24.8 (walk)

13

4.0

10

14:00-14.59

34.6 (run)

33.5 (walk)

27.3 (run)

26.6 (walk)

14

4.1

11

15:00-15:59

36.4 (run)

36.2 (walk)

28.6 (run)

28.5 (walk)

15

4.2

12

16:00-16:59

38.2 (run)

39.1 (walk)

29.8 (run)

30.4 (walk)

16

4.3

13

17:00-17:59

40.0 (run)

42.0 (walk)

31.1 (run)

32.5 (walk)

17

4.4

14

18:00-18:59

41.9 (run)

45.0 (walk)

32.4 (run)

34.6 (walk)

18

4.5

15

19:00-19:51

43.9 (run)

48.1 (walk)

33.8 (run)

36.7 (walk)

19

4.6

16

20:00-20:59

45.9 (run)

51.3 (walk)

35.2 (run)

39.0 (walk)

20

4.7

17

21:00

48.0 (run)

54.6 (walk)

36.6 (run)

41.2 (walk)
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